RecruitingPhase 4NCT05682131

South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigator
Xin Y Chen, Doctoral
Medical Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Intervention
Realgar Indigo naturalis formula(drug)
Enrollment
210 enrolled
Eligibility
1-14 years · All sexes
Timeline
2022 – 2030

Study locations (1)

Collaborators

First Affiliated Hospital, Sun Yat-Sen University · Third Affiliated Hospital, Sun Yat-Sen University · Zhujiang Hospital · The First Affiliated Hospital of Guangzhou Medical University · Guangzhou First People's Hospital · Huizhou Municipal Central Hospital · First Affiliated Hospital of Shantou University Medical College · Zhongshan People's Hospital, Guangdong, China · Zhongshan Bo Ai Hospital · First Affiliated Hospital of Guangxi Medical University · LiuZhou People's Hospital · Second Xiangya Hospital of Central South University · Hainan People's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05682131 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia →

← Back to all trials